Bray F, Laversanne M, Weiderpass E, Soerjomataram I (2021) The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127:3029–3030. https://doi.org/10.1002/cncr.33587

Article  PubMed  Google Scholar 

Ling S, Brown K, Miksza JK, Howells L, Morrison A, Issa E, Yates T, Khunti K, Davies MJ, Zaccardi F (2020) Association of type 2 diabetes with cancer: A Meta-analysis with Bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care 43:2313–2322. https://doi.org/10.2337/dc20-0204

Article  PubMed  Google Scholar 

Pearson-Stuttard J, Papadimitriou N, Markozannes G, Cividini S, Kakourou A, Gill D, Rizos EC, Monori G, Ward HA, Kyrgiou M, Gunter MJ, Tsilidis KK (2021) Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomization studies. Cancer Epidemiol Biomarkers Prev 30:1218–1228. https://doi.org/10.1158/1055-9965.EPI-20-1245

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986. https://doi.org/10.1056/NEJM199309303291401

Article  Google Scholar 

Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, Kaptoge S, Whitlock G, Qiao Q, Lewington S, Di Angelantonio E, Vander Hoorn S, Lawes CM, Ali MK, Mozaffarian D, Ezzati M (2013) Global burden of metabolic risk factors of chronic diseases collaborating, C. Asia-Pacific cohort studies, E. Diabetes epidemiology: collaborative analysis of diagnostic criteria in, C. Emerging risk factor, C. Prospective studies, the age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS ONE 8:e65174. https://doi.org/10.1371/journal.pone.0065174

Article  CAS  PubMed  PubMed Central  Google Scholar 

Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D, Vinicor F (2003) American diabetes, implications of the united Kingdom prospective diabetes study. Diabetes Care 26(1):S28–32. https://doi.org/10.2337/diacare.26.2007.s28

Article  PubMed  Google Scholar 

Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350:g7607. https://doi.org/10.1136/bmj.g7607

Article  PubMed  Google Scholar 

Koepsell H (2017) The Na(+)-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther 170:148–165. https://doi.org/10.1016/j.pharmthera.2016.10.017

Article  CAS  PubMed  Google Scholar 

Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733–794. https://doi.org/10.1152/physrev.00055.2009

Article  CAS  PubMed  Google Scholar 

Wright EM (2013) Glucose transport families SLC5 and SLC50. Mol Aspects Med 34:183–196. https://doi.org/10.1016/j.mam.2012.11.002

Article  CAS  PubMed  Google Scholar 

Barfuss DW, Schafer JA (1981) Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 241:F322–332. https://doi.org/10.1152/ajprenal.1981.241.3.F322

Article  CAS  PubMed  Google Scholar 

Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L (1991) Normalization of blood glucose in diabetic rats with Phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561–570. https://doi.org/10.1172/JCI115031

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2014) Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 62:1252–1262. https://doi.org/10.1111/jgs.12881

Article  PubMed  Google Scholar 

Riser Taylor S, Harris KB (2013) The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 33:984–999. https://doi.org/10.1002/phar.1303

Article  CAS  PubMed  Google Scholar 

Madunic IV, Madunic J, Breljak D, Karaica D, Sabolic I (2018) Sodium-glucose cotransporters: new targets of cancer therapy? Arh Hig Rada Toksikol 69:278–285. https://doi.org/10.2478/aiht-2018-69-3204

Article  CAS  PubMed  Google Scholar 

Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033. https://doi.org/10.1126/science.1160809

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS, Wallace WD, Magyar CE, Grogan TR, Elashoff D, Walser T, Yanagawa J, Aberle DR, Barrio JR, Dubinett SM, Shackelford DB (2018) Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med 10:eaat5933. https://doi.org/10.1126/scitranslmed.aat5933

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H (2018) Sodium glucose cotransporter 2 inhibitor Canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 142:1712–1722. https://doi.org/10.1002/ijc.31193

Article  CAS  PubMed  Google Scholar 

Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y (2017) Therapeutic effect of sodium glucose Co-Transporter 2 inhibitor Dapagliflozin on renal cell carcinoma. Med Sci Monit 23:3737–3745. https://doi.org/10.12659/msm.902530

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y (2019) The SGLT2 inhibitor Canagliflozin prevents carcinogenesis in a mouse model of diabetes and Non-AlcoholicSteatohepatitis-Related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int J Mol Sci 20:5237. https://doi.org/10.3390/ijms20205237

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Yang L, Mao L, Zhang L, Zhu Y, Xu Y, Cheng Y, Sun R, Zhang Y, Ke J, Zhao D (2022) SGLT2 Inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. Cancer Cell Int 22:74. https://doi.org/10.1186/s12935-022-02496-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardaweel S, Issa A (2022) Exploring the role of Sodium-Glucose cotransporter as a new target for Cancer therapy. J Pharm Pharm Sci 25:253–265. https://doi.org/10.18433/jpps32879

Article  PubMed  Google Scholar 

Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, Houde VP, Muti P, Tsakiridis T, Steinberg GR (2016) The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab 5:1048–1056. https://doi.org/10.1016/j.molmet.2016.08.014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T (2020) Effects of Canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS ONE 15:e0232283. https://doi.org/10.1371/journal.pone.0232283

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ (2019) SGLT2 Inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab 7:10. https://doi.org/10.1186/s40170-019-0203-1

Article  PubMed  PubMed Central  Google Scholar 

Ware K, Smith T, Brown DV, Hill D, Stewart L (2019) The effect of sodium glucose transporter 2 inhibitors on proliferation and growth factor signaling pathways in triple negative breast Cancer. FASEB J 33:64748. https://doi.org/10.1096/fasebj.2019.33.1_supplement.647.48

Article